Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2004 Jul;10(7):676-8.
doi: 10.1111/j.1469-0691.2004.00956.x.

Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients

Affiliations
Free PMC article
Clinical Trial

Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients

Y O Y Sooet al. Clin Microbiol Infect. 2004 Jul.
Free PMC article

Abstract

Treatment of severe acute respiratory syndrome (SARS) is experimental, and the effectiveness of ribavirin-steroid therapy is unclear. Forty SARS patients with progressive disease after ribavirin treatment and 1.5 g of pulsed methylprednisolone were given either convalescent plasma (n = 19) or further pulsed methylprednisolone (n = 21) in a retrospective non-randomised study. Good clinical outcome was defined as discharge by day 22 following the onset of symptoms. Convalescent plasma was obtained from recovered patients after informed consent. Patients in the plasma group had a shorter hospital stay (p 0.001) and lower mortality (p 0.049) than the comparator group. No immediate adverse effects were observed following plasma infusion.

Similar articles

Cited by192articles

References

    1. Lee N, Hui DS, Wu A et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003; 348: 1986–1994. -PubMed
    1. Ksiazek TG, Erdman D, Goldsmith CS et al. A novel coronavirus associated severe acute respiratory syndrome. N Engl J Med 2003; 348: 1953–1966. -PubMed
    1. Drosten C, Gunther S, Preiser W et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003; 348: 1967–1976. -PubMed
    1. Hui DS, Sung JJ. Severe acute respiratory syndrome. Chest 2003; 124: 12–15. -PMC-PubMed
    1. 中心说ease Control and Prevention. Update: severe acute respiratory syndrome. MMWR 2003; 52: 388–390. -PubMed

Publication types

MeSH terms

Substances